RxDoctor Payments Data

Ihab Dana, MD

Internal Medicine · Montrose, PANPI 1124009410

Payments from drug & device makers

$1,959in general payments, 2019–2025

Across 109 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$532
  • Pfizer$281
  • Bayer$144
  • Abbott$142
  • Boston Scientific$119
  • Lilly USA, LLC$104
  • plus $638 from 17 others

What the payments were for

  • Food & beverage$1,959100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,959 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$170,270
Medicare patients
537
Services billed
3,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban218$183,523
OzempicSemaglutide136$141,073
TrulicityDulaglutide38$38,749
JanuviaSitagliptin Phosphate50$31,402
XareltoRivaroxaban31$23,926
Lantus SolostarInsulin Glargine,hum.Rec.Anlog102$20,449
JardianceEmpagliflozin17$19,034
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog38$18,143
Novolog FlexpenInsulin Aspart52$14,830
RybelsusSemaglutide12$14,607
MounjaroTirzepatide13$13,068
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$12,845
Incruse ElliptaUmeclidinium Bromide36$11,909
Breo ElliptaFluticasone/Vilanterol30$11,280
Combivent RespimatIpratropium/Albuterol Sulfate20$10,370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$281$183,523218 claims
Novo NordiskOzempic, Rybelsus$532$155,680148 claims
Lilly USA, LLCTrulicity, Mounjaro$104$51,81751 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$57$36,03481 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Montrose

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →